Alembic Pharmaceuticals Ltd Q3 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 4
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- US business: Moderate growth expected despite pricing erosion; volume growth higher than revenue growth (~10% growth in rupee terms with significant price erosion).
- New product launches and injectables expected to drive incremental growth.
- API business: Anticipated to grow 10-15% annually, though Q4 may be lumpy due to big one-off orders.
- International markets (excluding US): Consistent ~10% growth noted; new projects being added.
- India business: Recorded 15% growth outperforming industry (10% growth), with strong segments being gynecology, anti-diabetics, ophthalmology, anti-infectives, and cough & cold.
- New facilities expected to start commercialization adding to growth, but expenses from these may pressure profits in the short term.
- Overall, $300-400 million US sales potential over 3-4 years, though timelines delayed by 2-3 years due to plant execution delays.
- R&D spend to be optimized to improve cost efficiency.
See what Alembic Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Alembic Pharmaceuticals Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Alembic Pharmaceuticals is incurring capital expenditure related to new facilities, with commercialization expected to start from the current quarter onwards.
- Annual run rate operating expenses for all new facilities are about Rs. 200 crores, with additional depreciation costs.
- Hard assets amount to approximately Rs. 1,200 crores, with the rest being accumulated pre-operative expenses.
- The new facilities include Onco, Onco-injectables, and oral solid dosage blocks.
- Commercial supplies for the new oncology facility are expected to start this quarter; Jarod facility operations may commence in FY ’24 or beyond.
- The company is focusing on R&D cost optimization and rationalization to offset incremental operating expenses from new plants.
- Alembic plans to reduce R&D expenses by 15%-20% in the next year while progressing with strategic investments in injectables and other product segments.
Track Alembic Pharmaceuticals Ltd — get its next earnings analysis in your feed
Margin guidance
Category 4- US business growth expected to be modest due to pricing erosion but new product launches and strong flu season contributed to 10% growth in Q3 FY23 (Page 6).
- R&D expenses targeted to reduce by 15-20% in FY24 to improve efficiency amid US market challenges (Pages 9-10).
- New facilities coming online will increase operating expenses, potentially pressuring profits in FY24 (Pages 11-12, 16).
- EBITDA margins and profit outlook uncertain for the next two years due to costs related to new plants and market conditions (Page 12).
- Long-term potential of US sales estimated around $300 to $400 million over next 3-4 years, but timelines pushed back by 2-3 years (Pages 15-16).
- Domestic business showing strong growth and outperformance, which can aid overall profitability (Pages 3-4).
- Overall organic growth expected from new facilities and product launches, with midterm focus on cost control to improve earnings.
Order book
- The company has not provided specific figures for the current or expected order book in the call.
- Mentioned the injectable approvals are in early stages with only a few product approvals so far.
- There is anticipation of a lot of bunching up of approvals from new plants over the next 12-24 months, indicating a backlog that will convert into commercial orders.
- Alembic anticipates seeing a faster approval rate moving forward post-compliance and remediation activities.
- API segment shows growth visibility with expectation of at least 10-15% growth year-on-year.
- The CMO business in API is described as "lumpy," with some large orders coming intermittently, contributing to orderbook fluctuations.
- Overall, while exact orderbook numbers are not disclosed, there is cautious optimism for growth driven by new plant approvals and increased commercialization activity in injectables and APIs.
How does Alembic Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Alembic Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Alembic Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Alembic Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…